E-LIB Suche - Ergebnisse für: Zhou, Keshu

1

Plain language summary of zanubrutinib or ibrutinib in chro..:

Brown, Jennifer R ; Eichhorst, Barbara ; Hillmen, Peter...
Future Oncology. 20 (2024) 12 - p. 717-726 , 2024

Link: https://doi.org/10.2217/..

2

Impact of tocilizumab on anti‐CD19 chimeric antigen recepto..:

Wang, Xiangmin ; Zhang, Bingpei ; Zhang, Qing...
Cancer. , 2024

Link: https://doi.org/10.1002/..

3

Improved efficacy and safety of zanubrutinib versus ibrutin..:

Zhou, Keshu ; Wang, Tingyu ; Pan, Ling...
Annals of Hematology. , 2024

Link: https://doi.org/10.1007/..

4

Discovery of a Novel and Potent LCK Inhibitor for Leukemia ..:

Guo, Hao ; Shen, Zhe-yuan ; Yuan, Yong-yi...
Journal of Chemical Information and Modeling. , 2024

Link: https://doi.org/10.1021/..

5

Dual-targeted CAR T-cell immunotherapies for hematological ..:

Yang, Jingyi ; Guo, Hao ; Han, Lu..
Experimental Hematology & Oncology. 13 (2024) 1 - p. , 2024

Link: https://doi.org/10.1186/..

6

Phase 1/2 multicenter trial of acalabrutinib in Chinese pat..:

Song, Yuqin ; Li, Jianyong ; Zhou, Keshu...
Leukemia & Lymphoma. 65 (2024) 5 - p. 647-652 , 2024

Link: https://doi.org/10.1080/..

7

Efficacy and safety of MIL62, a novel glycoengineered type ..:

Shi, Yuankai ; Zhou, Keshu ; Zhou, Hui...
eClinicalMedicine. 73 (2024) - p. 102702 , 2024

Link: https://doi.org/10.1016/..

8

Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, ..:

Song, Yuqin ; Malpica, Luis ; Cai, Qingqing...
The Lancet Oncology. 25 (2024) 1 - p. 117-125 , 2024

Link: https://doi.org/10.1016/..

9

Phase I study of the Syk inhibitor sovleplenib in relapsed ..:

Song, Yuqin ; Cao, Junning ; Zhang, Qingyuan...
Haematologica. , 2024

Link: https://doi.org/10.3324/..

10

P1099: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF PARSACL..:

Zheng, Zhong ; Zhang, Huilai ; Zhou, Keshu...
HemaSphere. 7 (2023) S3 - p. e1263860 , 2023

Link: https://doi.org/10.1097/..

11

Targeting cytohesin-1 suppresses acute myeloid leukemia pro..:

Ren, Wen-xiang ; Guo, Hao ; Lin, Sheng-yan...
Acta Pharmacologica Sinica. 45 (2023) 1 - p. 180-192 , 2023

Link: https://doi.org/10.1038/..

12

PB1929: EFFICACY AND SAFETY OF ACALABRUTINIB IN CHINESE PAT..:

Yang, Shenmiao ; Huang, Haiwen ; Zhou, Keshu...
HemaSphere. 7 (2023) S3 - p. e21928ec , 2023

Link: https://doi.org/10.1097/..

13

Low incidence of hepatitis B virus reactivation in patients..:

Yan, Zheng ; Luo, Xu-Feng ; Yao, Shu-Na...
Journal of Microbiology, Immunology and Infection. 56 (2023) 4 - p. 747-756 , 2023

Link: https://doi.org/10.1016/..

14

P626: A PHASE 1 STUDY EVALUATING THE SAFETY, TOLERABILITY, ..:

LI, Caixia ; Wei, Jia ; Peng, Liu...
HemaSphere. 7 (2023) S3 - p. e2710810 , 2023

Link: https://doi.org/10.1097/..

15

Treating relapsed/refractory mature T- and NK-cell neoplasm..:

Bachy, Emmanuel ; Savage, Kerry J. ; Huang, Huiqiang...
Blood Advances. 7 (2023) 16 - p. 4435-4447 , 2023

Link: https://doi.org/10.1182/..